NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Tuesday that it intends to sell 10 million shares of its common stock in a public offering.

The Carlsbad, Calif.-based molecular diagnostics company did not price the offering or say how much in proceeds it anticipates raising. It said, though, that net proceeds will be used for R&D efforts to expand its menu and develop its NexGen System testing platform, as well as to expand its US and global commercial operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.